- Home
- TRVI vs PVLA Comparison
TRVI vs PVLA Comparison
Compare TRVI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- PVLA
- Stock Information
- Founded
- TRVI 2011
- PVLA 2015
- Country
- TRVI United States
- PVLA United States
- Employees
- TRVI N/A
- PVLA N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- PVLA Health Care
- Exchange
- TRVI Nasdaq
- PVLA Nasdaq
- Market Cap
- TRVI 383.4M
- PVLA 308.2M
- IPO Year
- TRVI 2019
- PVLA N/A
- Fundamental
- Price
- TRVI $6.07
- PVLA $24.36
- Analyst Decision
- TRVI Strong Buy
- PVLA Strong Buy
- Analyst Count
- TRVI 8
- PVLA 7
- Target Price
- TRVI $17.56
- PVLA $44.43
- AVG Volume (30 Days)
- TRVI 1.6M
- PVLA 97.9K
- Earning Date
- TRVI 05-06-2025
- PVLA 05-15-2025
- Dividend Yield
- TRVI N/A
- PVLA N/A
- EPS Growth
- TRVI N/A
- PVLA N/A
- EPS
- TRVI N/A
- PVLA N/A
- Revenue
- TRVI N/A
- PVLA N/A
- Revenue This Year
- TRVI N/A
- PVLA N/A
- Revenue Next Year
- TRVI N/A
- PVLA N/A
- P/E Ratio
- TRVI N/A
- PVLA N/A
- Revenue Growth
- TRVI N/A
- PVLA N/A
- 52 Week Low
- TRVI $2.30
- PVLA $6.20
- 52 Week High
- TRVI $7.39
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- TRVI 54.54
- PVLA N/A
- Support Level
- TRVI $4.85
- PVLA N/A
- Resistance Level
- TRVI $6.15
- PVLA N/A
- Average True Range (ATR)
- TRVI 0.50
- PVLA 0.00
- MACD
- TRVI -0.04
- PVLA 0.00
- Stochastic Oscillator
- TRVI 73.94
- PVLA 0.00
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.